Daniel M. Skovronsky, M.D., Ph.D.
MYRIAD GENETICSAbout Daniel M. Skovronsky, M.D., Ph.D.
Independent Class I director at Myriad Genetics since July 2020; age 51 as of April 8, 2025. He is President of Lilly Research Laboratories, President of Lilly Immunology, and Chief Scientific Officer at Eli Lilly, with prior service as CEO and founder of Avid Radiopharmaceuticals (founded in 2004). Education: B.S. in molecular biophysics and biochemistry (Yale), M.D. and Ph.D. in neuroscience (University of Pennsylvania). His current board term runs through the 2027 Annual Meeting; the Board has determined he is independent. Committee memberships: Compensation and Human Capital Committee (CHCC) and Research and Product Innovation Committee (RPIC).
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Avid Radiopharmaceuticals Inc. | Founder and Chief Executive Officer | Founded 2004 | Led development of diagnostic products; entrepreneurial expertise cited by MYGN Board |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Eli Lilly and Company | President, Lilly Research Laboratories; President, Lilly Immunology; Chief Scientific Officer | Current | R&D leadership and scientific expertise leveraged for MYGN product innovation oversight |
Board Governance
- Independence: Board determined Skovronsky is an independent director under Nasdaq rules.
- Committee assignments: Member of CHCC (independent committee) and RPIC; not a chair. CHCC met 5 times in 2024; RPIC met 3 times in 2024.
- Attendance: Board met 10 times in 2024; no director attended fewer than 75% of Board and committee meetings.
- Board structure: Separate Chair and CEO roles; majority independent directors; regular executive sessions of independent directors.
- Term and classification: Class I director; term ends at 2027 Annual Meeting.
- Governance controls: Anti-hedging/anti-pledging policy; clawback policy adopted per SEC/Nasdaq; robust director stock ownership guidelines.
Fixed Compensation
| Component (2024) | Amount (USD) | Notes |
|---|---|---|
| Annual Board retainer | $60,000 | Standard cash retainer for non-employee directors |
| CHCC membership fee | $10,000 | Member (non-chair) |
| RPIC membership fee | $13,500 | Member (non-chair) |
| Total cash fees (reported) | $83,500 | Matches reported cash fees for Skovronsky |
Performance Compensation
| Equity Award | Grant Date | Shares/Units | Fair Value (USD) | Vesting Terms |
|---|---|---|---|---|
| RSUs (director annual grant) | 2024-06-06 | 15,695 | $349,999 | Vest upon earlier of one year of service or next annual meeting |
- Director equity program: Annual RSU grants sized at $350,000 grant-date value; no options; no meeting fees; equity awards subject to minimum one-year vesting, limited acceleration, and no dividends before vesting.
Other Directorships & Interlocks
| Category | Details |
|---|---|
| Current public company boards | None disclosed for Skovronsky |
| Third-party compensation arrangements for directors | None; Board disclosed no arrangements beyond MYGN compensation for directors/nominees |
| Related-party transactions (Item 404) | None with related persons since Jan 1, 2024 |
Expertise & Qualifications
- Medical and scientific background with deep R&D leadership in diagnostics and neuroscience; supports MYGN’s product development.
- Board capability matrix flags finance/accounting, leadership, healthcare industry, and diagnostics industry expertise.
- RPIC role aligns with his technical and product innovation expertise.
Equity Ownership
| Metric | Value | Notes |
|---|---|---|
| Total beneficial ownership | 86,010 shares | Includes 15,695 RSUs vesting within 60 days of April 8, 2025; less than 1% of outstanding shares |
| Unvested RSUs (12/31/2024) | 15,695 | From 2024 annual director grant |
| Ownership guidelines | 5x annual cash retainer for directors; 5-year compliance window; RSUs with time-based vest count toward compliance | |
| Anti-hedging/pledging | Hedging and pledging of MYGN securities prohibited under Insider Trading Policy |
Governance Assessment
- Signals supporting investor confidence: Independence affirmed; no related-party transactions or third-party compensation for directors; strong attendance; robust stock ownership guidelines; anti-hedging/pledging; and clawback policy compliance.
- Committee effectiveness: CHCC is fully independent and uses Mercer as an independent compensation consultant; RPIC provides structured oversight of product and R&D initiatives aligned with Skovronsky’s expertise.
- Potential conflict considerations: Skovronsky’s senior executive role at Eli Lilly could present perceived conflicts in R&D or commercial contexts; however, MYGN’s NGC and AFC policies govern conflicts and related-party transactions, and none are disclosed.
- RED FLAGS: None evidenced in filings—no low attendance, no related-party transactions, no hedging/pledging, no third-party director compensation arrangements.